(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
This study, called PIONEER, is for people in the UK with indolent systemic mastocytosis (ISM) whose symptoms aren't fully controlled by their current treatment. We're looking at a new drug called avapritinib. This drug aims to block a specific protein involved in ISM. Researchers want to see how effective and safe avapritinib is compared to a dummy pill (placebo). Participants will start with either avapritinib or placebo, alongside their usual care. Later, everyone in the study will get avapritinib. This helps scientists understand if the new drug can make a real difference to people's symptoms and well-being.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is called PIONEER and it's looking into a health condition called indolent systemic mastocytosis (ISM). ISM is a rare condition where certain cells, called mast cells, build up in different parts of the body. This can cause various symptoms like skin rashes, stomach problems, and tiredness, which can really affect daily life. For some people, these symptoms are hard to control even with their usual treatments.
The main goal of this study is to test a new medicine called avapritinib. This drug works by targeting a specific problem within the mast cells, which scientists hope will reduce the number of mast cells and help ease symptoms. The study will compare avapritinib with a 'placebo', which is a dummy pill that looks just like the study drug but contains no active medicine. This comparison helps researchers scientifically prove if avapritinib is truly effective and safe.
Throughout the study, all participants will also receive what's called 'best supportive care'. This means you'll continue to get the treatments and care your doctor usually recommends to manage your symptoms. The study is divided into three parts. In the first part, people will receive either avapritinib or the placebo. In the third part, everyone in the study will get to take avapritinib, including those who were initially on the placebo. This setup ensures that everyone eventually has the chance to try the new treatment.
النقاط الرئيسية
- Tests a new medicine (avapritinib) for indolent systemic mastocytosis (ISM).
- Compares avapritinib to a dummy pill (placebo) first, then everyone gets the new drug.
- Aims to relieve symptoms not well controlled by current treatments.
- Involves regular health checks and symptom assessments.
- Open to adults aged 18 and over with confirmed ISM.
- Your usual medical care continues alongside the study.
من قد يكون مؤهلاً؟
To join this study, you must be 18 years or older and have a confirmed diagnosis of indolent systemic mastocytosis (ISM). Your ISM symptoms should be moderate to severe, and your current treatment shouldn't be fully controlling at least one of your main symptoms. You'll also need to be generally well enough to take part in the study activities.
There are some reasons why you wouldn't be able to join. For example, if you have a different type of mastocytosis (like aggressive mastocytosis or mast cell leukaemia), or if you've recently used avapritinib or certain other treatments. Your doctor will carefully check all the requirements to see if this study is suitable for you.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك 18 سنة أو أكثر؟
- Do you have a confirmed diagnosis of indolent systemic mastocytosis (ISM)?
- Are your ISM symptoms moderate to severe and not fully controlled by your current treatment?
- Have you avoided certain treatments recently, as checked by your doctor?
- Do you feel well enough for regular clinic visits and tests?
- Have you not previously taken this specific study drug, avapritinib?
ماذا يتضمن المشاركة؟
If you decide to take part in this study, you will be randomly assigned to either receive the study drug, avapritinib, or a placebo (dummy pill) for the first part of the study, lasting several months. Both groups will also continue with their usual care. After this initial period, everyone in the study will receive avapritinib for the third part of the study.
Participation will involve regular visits to the study clinic for health checks, blood tests, and to assess your symptoms. You will also complete questionnaires about your symptoms and how you are feeling. The exact number of visits and the total duration aren't specified but are typical for a Phase 2 study. Your doctor will explain how often you'll need to attend and what each visit will involve.
المخاطر والفوائد المحتملة
المواقع (49)
- جامعة ألاباما في برمنغهامالرمز البريدي المؤكدبرمنغهام، الولايات المتحدة
- مستشفى مايو كلينكالرمز البريدي المؤكدفينيكس، الولايات المتحدة
- معهد ستانفورد للسرطانالرمز البريدي المؤكدستانفورد، الولايات المتحدة
- مايو كلينك فلوريداالرمز البريدي المؤكدجاكسونفيل، الولايات المتحدة
- H. Lee Moffitt Cancer Centerالرمز البريدي المؤكدتامبا، الولايات المتحدة
- معهد وينشيب للسرطان، جامعة إيموريالرمز البريدي المؤكدأتلانتا، الولايات المتحدة
- مركز جامعة روش الطبيالرمز البريدي المؤكدشيكاغو، الولايات المتحدة
- University of Kansas Hospitalالرمز البريدي المؤكدكانساس سيتي، الولايات المتحدة
- Brigham & Women's Hospitalالرمز البريدي المؤكدبوسطن، الولايات المتحدة
- معهد دانا فاربر للسرطانالرمز البريدي المؤكدبوسطن، الولايات المتحدة
- Michigan Medicine, University of Michiganالرمز البريدي المؤكدآن آربر، الولايات المتحدة
- عيادة مايوالرمز البريدي المؤكدروتشستر، الولايات المتحدة
أسئلة شائعة
What is indolent systemic mastocytosis (ISM)?
ISM is a rare condition where special immune cells, called mast cells, build up in different body tissues, causing a range of symptoms.
What is avapritinib?
Avapritinib is a new drug being tested that aims to block a specific protein signal that contributes to the growth of mast cells in ISM.
ما هو الدواء الوهمي؟
A placebo is a 'dummy' pill that looks just like the real medicine but contains no active drug. It helps researchers understand if the new drug is truly effective.
هل سأحصل بالتأكيد على الدواء الجديد؟
In the first part of the study, you'll have a 50/50 chance of getting avapritinib or the placebo. However, everyone will get avapritinib in the third part of the study.
من الذي يدير هذه الدراسة؟
This study is called PIONEER and is being conducted by Blueprint Medicines, working with doctors and hospitals.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.